Deals channel feed – Endpoints News

Deals channel feed

Aurinia will explore possible sale, following push by shareholder

Last year

FTC and DOJ propose changes that could slow dealmaking review process

Last year

Eli Lilly to buy diabetes cell therapy partner Sigilon, expanding bet on preclinical program

Last year

Xentria and Meitheal ink licensing deal for rare lung disease treatment in North America

Last year

Shionogi takes antibiotic maker under its wing in $100M cash buyout

Last year

MPP signs on four generics makers to make Novartis' Tasigna more accessible

Last year

AstraZeneca, Sanofi turn to Alphabet spinout's AI and quantum technologies for drug discovery

Last year

Corrected: Prime Medicine partners with Versant-backed biotech to develop safer stem cell transplants

Last year

Aslan outlicenses atopic dermatitis antibody in $138.5M deal

Last year

Aeglea BioTherapeutics acquires startup Spyre in bid to go after Merck’s Prometheus, Roivant’s Telavant

Last year

Tourmaline Bio reverse merges into Talaris and raises funds to target thyroid eye disease and pharma rivals

Last year

‘The sleeping giant is waking up’: FTC raises the pressure on pharma dealmaking

Last year

Despite a dip in M&A value and volume, PwC predicts deal activity to remain strong with an uptick in IPOs

Last year

Swiss biotech unloads US rights to Duchenne candidate for $231M

Last year

Lilly inks $2.4B cash deal to buy DICE and its immunology pipeline

Last year

Coherus to buy Surface Oncology in stock deal valued at $65M

Last year

AstraZeneca enlists an upstart China biotech partner in the wake of an R&D setback

Last year

Astellas shells out $35M upfront to Cullgen in protein degrader development deal

Last year

Verve snags $60M from Lilly to tackle Lp(a) with one-time gene editing

Last year

Biogen lines up potential deal for ALS drug, doubling down on neurofilament biomarker

Last year

AstraZeneca amps environmental goals with deal for renewable fuel use at all US sites

Last year

Erytech blasts activist investor's attempt to block reverse merger, Akkadian proposes new board in return

Last year

Novartis adds $3.2B cash deal to M&A tally, snapping up Chinook and its late-stage kidney drugs

Last year

Oslo biotech finds another merger partner after shareholders rejected November offer

Last year

First page Previous page 33 34 353637 38 39 Next page Last page